Aptinyx’s Development Pipeline
Aptinyx’s proprietary chemistry platform has yielded numerous small-molecule modulators of N-methyl-D-aspartate (NMDA) receptors. While all of the product candidates from our discovery platform modulate NMDA receptors, each one is a distinct chemical entity with unique pharmacologic properties. We evaluate the therapeutic implications of variations in these properties by interrogating our molecules across different preclinical models of brain and nervous system disorders. The data we collect from these preclinical studies indicate which molecules are better suited for different indications and inform our development decisions accordingly.
A number of these molecules have advanced into clinical development as product candidates for the treatment of various brain and nervous system disorders. In studies to date, they have demonstrated high oral bioavailability, diverse NMDA-receptor subtype binding profiles, and differentiated activity. Aptinyx’s product candidates bind within a previously uncharacterized binding domain, or “pocket,” on the NMDA receptor to modulate NMDA-receptor channel opening and enhance synaptic plasticity. This mechanism is distinct from any other therapies, emerging or marketed, for multiple challenging neurologic disorders.